These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 30627312

  • 1. [Cardiovascular and metabolic impact of glucocorticoid substitution therapy in patients with Addison's disease].
    Salah DB, Charfi N, Elleuch M, Kacem FH, Rekik N, Mnif M, Mnif F, Abid M.
    Pan Afr Med J; 2018; 30():251. PubMed ID: 30627312
    [Abstract] [Full Text] [Related]

  • 2. Recurrent nocturnal hypoglycaemia as a cause of morning fatigue in treated Addison's disease--favourable response to dietary management: a case report.
    Petersen KS, Rushworth RL, Clifton PM, Torpy DJ.
    BMC Endocr Disord; 2015 Oct 24; 15():61. PubMed ID: 26500000
    [Abstract] [Full Text] [Related]

  • 3. [Metabolic assessment of hydrocortisone replacement therapy in patients with primary adrenocortical insufficiency].
    Fichna M, Gryczyńska M, Sowińska A, Sowiński J.
    Przegl Lek; 2011 Oct 24; 68(2):96-102. PubMed ID: 21751518
    [Abstract] [Full Text] [Related]

  • 4. Salivary cortisol day curves in assessing glucocorticoid replacement therapy in Addison's disease.
    Smans L, Lentjes E, Hermus A, Zelissen P.
    Hormones (Athens); 2013 Oct 24; 12(1):93-100. PubMed ID: 23624135
    [Abstract] [Full Text] [Related]

  • 5. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy.
    Björnsdottir S, Øksnes M, Isaksson M, Methlie P, Nilsen RM, Hustad S, Kämpe O, Hulting AL, Husebye ES, Løvås K, Nyström T, Bensing S.
    Clin Endocrinol (Oxf); 2015 Jul 24; 83(1):28-35. PubMed ID: 25400085
    [Abstract] [Full Text] [Related]

  • 6. Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison's disease on glucocorticoid and mineralocorticoid replacement therapy.
    Camozzi V, Betterle C, Frigo AC, Zaccariotto V, Zaninotto M, De Caneva E, Lucato P, Gomiero W, Garelli S, Sabbadin C, Salvà M, Costa MD, Boscaro M, Luisetto G.
    Endocrine; 2018 Feb 24; 59(2):319-329. PubMed ID: 28795340
    [Abstract] [Full Text] [Related]

  • 7. Investigation of glucocorticoid receptor polymorphisms in relation to metabolic parameters in Addison's disease.
    Ross IL, Levitt NS, Van der Merwe L, Schatz DA, Johannsson G, Dandara C, Pillay TS, Blom DJ.
    Eur J Endocrinol; 2013 Mar 24; 168(3):403-12. PubMed ID: 23239757
    [Abstract] [Full Text] [Related]

  • 8. An assessment of bone mineral density in patients with Addison's disease and isolated ACTH deficiency treated with glucocorticoid.
    Chikada N, Imaki T, Hotta M, Sato K, Takano K.
    Endocr J; 2004 Jun 24; 51(3):355-60. PubMed ID: 15256782
    [Abstract] [Full Text] [Related]

  • 9. Current and emerging therapies for Addison's disease.
    Napier C, Pearce SH.
    Curr Opin Endocrinol Diabetes Obes; 2014 Jun 24; 21(3):147-53. PubMed ID: 24755997
    [Abstract] [Full Text] [Related]

  • 10. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.
    Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A, Berardelli R, Karamouzis I, Lucchiari M, Manetta T, Mengozzi G, Arvat E, Ghigo E.
    Endocrine; 2016 Feb 24; 51(2):360-8. PubMed ID: 26184416
    [Abstract] [Full Text] [Related]

  • 11. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.
    Oksnes M, Björnsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM, Broman JE, Triebner K, Kämpe O, Hulting AL, Bensing S, Husebye ES, Løvås K.
    J Clin Endocrinol Metab; 2014 May 24; 99(5):1665-74. PubMed ID: 24517155
    [Abstract] [Full Text] [Related]

  • 12. Glucocorticoid replacement therapy in patients with Addison's disease.
    Kyriazopoulou V.
    Expert Opin Pharmacother; 2007 Apr 24; 8(6):725-9. PubMed ID: 17425469
    [Abstract] [Full Text] [Related]

  • 13. BClI polymorphism of the glucocorticoid receptor gene is associated with increased obesity, impaired glucose metabolism and dyslipidaemia in patients with Addison's disease.
    Giordano R, Marzotti S, Berardelli R, Karamouzis I, Brozzetti A, D'Angelo V, Mengozzi G, Mandrile G, Giachino D, Migliaretti G, Bini V, Falorni A, Ghigo E, Arvat E.
    Clin Endocrinol (Oxf); 2012 Dec 24; 77(6):863-70. PubMed ID: 22587831
    [Abstract] [Full Text] [Related]

  • 14. Addison's disease in pregnancy: Case report, management, and review of the literature.
    Margulies SL, Corrigan K, Bathgate S, Macri C.
    J Neonatal Perinatal Med; 2020 Dec 24; 13(2):275-278. PubMed ID: 31744021
    [Abstract] [Full Text] [Related]

  • 15. [Evaluation of corticosteroid replacement therapy and its effect on bones in Addison's disease].
    Heureux F, Maiter D, Boutsen Y, Devogelaer JP, Jamart J, Donckier J.
    Ann Endocrinol (Paris); 2000 Sep 24; 61(3):179-83. PubMed ID: 10970940
    [Abstract] [Full Text] [Related]

  • 16. Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial.
    Gagliardi L, Nenke MA, Thynne TR, von der Borch J, Rankin WA, Henley DE, Sorbello J, Inder WJ, Torpy DJ.
    J Clin Endocrinol Metab; 2014 Nov 24; 99(11):4149-57. PubMed ID: 25127090
    [Abstract] [Full Text] [Related]

  • 17. Replacement therapy for Addison's disease: recent developments.
    Løvås K, Husebye ES.
    Expert Opin Investig Drugs; 2008 Apr 24; 17(4):497-509. PubMed ID: 18363515
    [Abstract] [Full Text] [Related]

  • 18. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone.
    Løvås K, Gjesdal CG, Christensen M, Wolff AB, Almås B, Svartberg J, Fougner KJ, Syversen U, Bollerslev J, Falch JA, Hunt PJ, Chatterjee VK, Husebye ES.
    Eur J Endocrinol; 2009 Jun 24; 160(6):993-1002. PubMed ID: 19282465
    [Abstract] [Full Text] [Related]

  • 19. Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison's disease.
    Pearce SH, Mitchell AL, Bennett S, King P, Chandran S, Nag S, Chen S, Smith BR, Isaacs JD, Vaidya B.
    J Clin Endocrinol Metab; 2012 Oct 24; 97(10):E1927-32. PubMed ID: 22767640
    [Abstract] [Full Text] [Related]

  • 20. Akinetic mutism followed by a manic reaction on introduction of steroid replacement for Addison's disease.
    Kalambokis G, Konitsiotis S, Pappas D, Tsianos EV.
    J Endocrinol Invest; 2006 Mar 24; 29(3):257-60. PubMed ID: 16682841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.